The subscription period begins in Modus Therapeutics Holding AB's issue of units prior to planned listing on Nasdaq First North Growth Market
STOCKHOLM, SWEDEN – 29 June 2021: Today, the subscription period begins in Modus Therapeutics Holding AB (“Modus Therapeutics” or “the Company”) issue of units (“the Listing Issue”) prior to the planned listing on the Nasdaq First North Growth Market (“First North”). The subscription period runs until 13 July 2021. If the Listing Issue is fully subscribed, the Company will initially receive approximately SEK 33 million and in approximately one year, a further maximum of approximately SEK 45 million may be added to Modus Therapeutics through a warrant exercise. The Company has, through